Combining MGI's new NGS sequencing equipment with NGeneBio's cancer precision diagnosis product

Hand in hand to preoccupy the Asian region... Expansion of global distribution in the future

Seoul, South Korean, 18 August, 2023 - NGeneBio (354200, CEO Choi Chul Choi), a company specializing in next-generation sequencing-based precision diagnosis platform, announced on the 18th that it had signed a business agreement with MGI, the largest NGS company in China and a global NGS equipment manufacturer.

Founded in 2016, MGI is a leading producer of clinical high-throughput gene sequencers with over 2,800 employees, providing products and services in more than 90 countries and regions around the world, and serving more than 2,400 customers. In addition, as a company committed to building core tools and technology to lead life science, it has grown to become one of the two companies in the world that can independently develop and mass-produce low-, medium- and high-throughput clinical gene sequencers from GB to TB in about 7 years since its establishment. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation that can be applied to precision medicine, precision agriculture, precision healthcare and other relevant industries.

Through this business agreement, the two sides will ▲apply NGeneBio’s NGS cancer precision diagnosis product to MGI’s NGS platform DNBSEQ-G99 sequencer , ▲joint local cooperation in Asia (Singapore, Thailand, Malaysia, Taiwan, Philippines, Indonesia, Vietnam, China, etc.) They plan to strengthen their competitiveness in the precision medical field by promoting commercialization, ▲joint marketing and ▲global distribution cooperation, and ▲promoting joint business development such as equipment and NGS diagnostic product package production.